Replies to post #216410 on Biotech Values

[CT]

Re: RVNC PF

Advancement to a 2b is the absolute wrong goal for shareholders in the long run. A successful outcome of a well designed trial is my preferred goal.

As I've said before, I've never liked the PF indication for RVNC's drug (or any drug for that matter). Too difficult to diagnose correctly.

[jbog]

In any event, the PF indication is not (and never was) a material part of the valuation thesis for RVNC outlined in #msg-136931624, which remains unchanged.

I'll agree that by your metric's the valuation hasn't changed, but what has changed is the impression of Revance's toxin being 'better' than Botox.

It was probably a mistake to go after PF, and it'll be even a bigger mistake to chase it. Very hard to define the patient pool.

[DewDiligence]

(RVNC)—Boston Globe write-up on plantar fasciitis:

https://www.bostonglobe.com/metro/2018/10/19/welcome-plantar-fasciitis-nation/cSeEupijM5jvhfnugysRiP/story.html